BEYOND AIR INC. - COMMON STOCK

Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease

16 фев 2021 07:00:11 Источник Nasdaq GlobeNewswire

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update

09 фев 2021 15:05:00 Источник Nasdaq GlobeNewswire

Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast

15 янв 2021 15:10:00 Источник Nasdaq GlobeNewswire